Cargando…
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis
BACKGROUND: Patients with decompensated cirrhosis are excluded or underrepresented in clinical trials of systemic therapies for hepatocellular carcinoma (HCC) and comparisons of available therapies are lacking. We aimed to compare overall survival for patients with HCC and Child‐Pugh B cirrhosis tre...
Autores principales: | Chapin, William J., Hwang, Wei‐Ting, Karasic, Thomas B., McCarthy, Anne Marie, Kaplan, David E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844625/ https://www.ncbi.nlm.nih.gov/pubmed/35652419 http://dx.doi.org/10.1002/cam4.4906 |
Ejemplares similares
-
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
por: FEDERICO, ALESSANDRO, et al.
Publicado: (2015) -
Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study
por: Labeur, Tim A., et al.
Publicado: (2019) -
Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy
por: Hasan, Shaakir, et al.
Publicado: (2017) -
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
por: Liu, Chen-Hua, et al.
Publicado: (2021) -
Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis
por: Hiroshima, Yuichi, et al.
Publicado: (2023)